Prescribing Clinical Network

**Policy Statement**

Memantine in combination with an Acetylcholinesterase inhibitor for the management of Behavioural and Psychological Symptoms of Dementia (BPSD) in primary care

**Policy No:**

PCN 275 -2017

**Date of Issue**

September-2017

**Review Date:**

September -2020

*(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)*

**Recommendations:**

The Prescribing Clinical Network recommends the use of memantine in combination with acetylcholinesterase inhibitors for adults with Behavioural and Psychological Symptoms of Dementia (BPSD) when prescribing is initiated by specialists within Surrey and Borders Partnership NHS Trust.

Memantine in combination with acetylcholinesterase inhibitors will be considered as BLUE (with information sheet) on the traffic light system with a minimum of 3 months prescribed in secondary care.

Please note; Memantine and the acetylcholinesterase inhibitor will be prescribed as their respective products and not as a combination product.

**Key Considerations:**

- The PCN was assured that the proper pre-initiation prescribing considerations are followed if prescribing is initiated by specialists within Surrey and Borders Partnership NHS Trust.

**Date taken to Prescribing Clinical Network**

6th September 2017

**Agreed by PCN members**

22nd September 2017

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG